Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
News
Sports
TV & Film
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts115/v4/b7/5e/0e/b75e0e66-d1e5-b31e-6eb2-cd134a385649/mza_18369675551325857977.jpg/600x600bb.jpg
Drug Target Review Podcast
Drug Target Review
41 episodes
1 week ago
This episode, 'Plasmids: Tackling Supply Chain and Manufacturing Challenges,' explores the critical supply chain and manufacturing hurdles impacting the life science industry, especially in gene therapy. We'll uncover effective strategies for securing plasmids of the necessary grades, vital for advancing life-changing treatments. Join us as we speak with Matthew Hewitt, Vice President and Technical Officer for CGT & Biologics at Charles River Laboratories. Matthew will explore: - Strategies for providing plasmids across all necessary grades, ensuring quality and consistency. - How process standardization can significantly simplify complex supply chains. - The crucial role of maintaining larger material stocks to overcome long-lead time consumable issues. - How these integrated approaches collectively streamline operations and accelerate gene therapy advancements. - His expert insights on the future trajectory of gene therapy.
Show more...
Science
RSS
All content for Drug Target Review Podcast is the property of Drug Target Review and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
This episode, 'Plasmids: Tackling Supply Chain and Manufacturing Challenges,' explores the critical supply chain and manufacturing hurdles impacting the life science industry, especially in gene therapy. We'll uncover effective strategies for securing plasmids of the necessary grades, vital for advancing life-changing treatments. Join us as we speak with Matthew Hewitt, Vice President and Technical Officer for CGT & Biologics at Charles River Laboratories. Matthew will explore: - Strategies for providing plasmids across all necessary grades, ensuring quality and consistency. - How process standardization can significantly simplify complex supply chains. - The crucial role of maintaining larger material stocks to overcome long-lead time consumable issues. - How these integrated approaches collectively streamline operations and accelerate gene therapy advancements. - His expert insights on the future trajectory of gene therapy.
Show more...
Science
https://i1.sndcdn.com/avatars-fPsLpct3hY9xg31d-3i0CyQ-original.jpg
How mRNA technology could revolutionise therapeutics
Drug Target Review Podcast
31 minutes 30 seconds
1 year ago
How mRNA technology could revolutionise therapeutics
In this podcast episode, we will be discussing how mRNA vaccines for cancer treatment engage with the immune system to illicit an anti-tumour response, how they could synergise with other cancer treatments, as well as which cancers show most promise for this approach. This conversation features Dr Rebecca Boohaker, Director of Oncology at Southern Research, and Fusataka Koide, Senior Director of Business Development at Southern Research.
Drug Target Review Podcast
This episode, 'Plasmids: Tackling Supply Chain and Manufacturing Challenges,' explores the critical supply chain and manufacturing hurdles impacting the life science industry, especially in gene therapy. We'll uncover effective strategies for securing plasmids of the necessary grades, vital for advancing life-changing treatments. Join us as we speak with Matthew Hewitt, Vice President and Technical Officer for CGT & Biologics at Charles River Laboratories. Matthew will explore: - Strategies for providing plasmids across all necessary grades, ensuring quality and consistency. - How process standardization can significantly simplify complex supply chains. - The crucial role of maintaining larger material stocks to overcome long-lead time consumable issues. - How these integrated approaches collectively streamline operations and accelerate gene therapy advancements. - His expert insights on the future trajectory of gene therapy.